OALib Journal期刊
ISSN: 2333-9721
费用：99美元

投递稿件

查看量	下载量

相关文章
更多...

华西医学 2014

培美曲塞或紫杉醇联合顺铂治疗晚期肺腺癌的近期疗效比较

DOI: 10.7507/1002-0179.20140617, PP. 2042-2045

陈琳,吴琦

Keywords: 肺腺癌,培美曲塞,紫杉醇,顺铂

Full-Text Cite this paper Add to My Lib

Abstract:

目的　比较培美曲塞联合顺铂方案与紫杉醇联合顺铂方案治疗晚期肺腺癌的近期疗效及不良反应。方法　对2009年1月－2012年12月收治入院的Ⅲ～Ⅳ期肺腺癌患者，根据患者意愿分为培美曲塞联合顺铂组（PP组）63例和紫杉醇联合顺铂组（TP组）61例，每组完成2个周期化学治疗（化疗）后进行疗效评价。结果　PP组和TP组有效率分别为58.7%、37.7%，疾病控制率分别为74.6%、52.5%，中位无进展生存期分别为6.1、4.5个月，两组比较差异均有统计学意义（P＜0.05）。PP组的恶心呕吐、白细胞减少发生率低于TP组，差异有统计学意义（χ2=16.164，P＜0.001；χ2=9.469，P=0.002）；血小板减少、贫血、肝肾功能损害发生率两组差异有统计学意义（χ2=0.098，P=0.755；χ2=0.267，P=0.606；χ2=0.006，P=0.973）。结论　对于肺腺癌，培美曲塞联合顺铂方案较紫杉醇联合顺铂有更好的近期疗效，且不良反应较轻。

References

[1]	[ 1 ]　Pirker R, Minar W. Chemotherapy of advanced non-small cell lung cancer[J]. Front Radiat Ther Oncol, 2010, 42: 157-163.
[2]	[ 2 ]　Kim YH, Kim JS, Choi YH, et al. Phase Ⅱ study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer[J]. Int J Clin Oncol, 2002, 7(2): 114-119.
[3]	[ 3 ]　Ricciardi S, Tomao S, de Marinis F. Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer[J]. Ther Clin Risk Manag, 2009, 5: 781-787.
[4]	[ 4 ]　Cohen MH, Cortazar P, Justice R, et al. Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC)[J]. Oncologist, 2010, 15(12): 1352-1358.
[5]	[ 5 ]　Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors[J]. J Nucl Med, 2009, 50(Suppl 1): 122S-150S.
[6]	[ 6 ]　孙燕, 周际昌. 临床肿瘤内科手册[M]. 4版. 北京: 人民卫生出版社, 2003: 97-107.
[7]	[ 7 ]　Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med, 2002, 346(2): 92-98.
[8]	[ 8 ]　Rollins KD, Lindley C. Pemetrexed: a multitargeted antifolate[J]. Clin Ther, 2005, 27(9): 1343-1382.
[9]	[ 9 ]　Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications[J]. Mol Cancer Ther, 2007, 6(2): 404-417.
[10]	张静, 范继业, 程艳坤, 等. 培美曲塞二钠的合成研究进展[J]. 河北化工, 2009, 32(5): 5-6, 21.
[11]	Standfield L, Weston AR, Barraclough H, et al. Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidence[J]. Respirology, 2011, 16(8): 1210-1220.
[12]	姜金, 李伦, 王晓晶, 等. 培美曲塞联合铂类对比吉西他滨联合铂类治疗晚期非小细胞肺癌的meta分析[J]. 中国肺癌杂志, 2011, 14(1): 43-48.
[13]	Chen M, Shao W, He J, et al. Role of pemetrexed and platinums combination in patients with non-small cell lung cancer[J]. Curr Drug Targets, 2010, 11(1): 29-36.
[14]	廖日强, 吴一龙. 培美曲塞在肺癌治疗中的新进展[J]. 中国处方药, 2010, 3(3): 46-49.
[15]	Scagliotti GV, Parikh P, Von Pawel J, et al. PhaseⅢ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer[J]. J Clin Oncol, 2008, 26(21): 3543-3551.
[16]	Omlin A, D’addario G, Gillessen S, et al. Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung[J]. Lung Cancer, 2009, 65(3): 383-384.
[17]	Ongali B, Hellal F, Rodi D, et al. Autoradiographic analysis of mouse brain kinin B1 and B2 receptors after closed head trauma and ability of Anatibant mesylate to cross the blood-brain barrier[J]. J Neurotrauma, 2006, 23(5): 696-707.
[18]	Dogan M, Yalcin B, Utkan G, et al. Activity of pemetrexed on brain metastases from non-small cell lung cancer: what is the mechanism[J]. Lung Cancer, 2009, 66(3): 399.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133